More recently, CD39 ATPase activity and Treg frequency increased relative to HCs in RRMS patients who underwent immunomodulatory treatment, such as IFN-β, glatiramer acetate (GA), natalizumab, or fingolimod [26,27]. The gene discussed is ENTPD1; the disease is relapsing-remitting multiple sclerosis.